GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Price-to-Funds-From-Operations

Moleculin Biotech (FRA:MOL) Price-to-Funds-From-Operations : (As of Jun. 20, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Moleculin Biotech (FRA:MOL) Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.